Table 3.
Prevalence of aPL in patients with obstetric complications and healthy controls.
| Healthy controls n = 87 (%) | Non-APS obstetric manifestation n = 42 (%) | Pregnancy loss defined by APS criteria [1] n = 169 (%) | |
|---|---|---|---|
| LA | 0 | 2 (5.3)* | 13 (8.7)** |
| aCL | 2 (2.3) | 2 (4.8) | 21 (12.4) |
| IgG | 1 (1.2) | 2 (4.8) | 17 (10.1) |
| IgM | 1 (1.2) | 0 | 6 (3.6) |
| anti-β 2GPI | 6 (6.9) | 3 (7.1) | 12 (7.1) |
| IgG | 6 (6.9) | 3 (7.1) | 10 (5.9) |
| IgM | 0 | 0 | 4 (2.4) |
| aPS/PT | 2 (2.3) | 0 | 22 (13.0) |
| IgG | 1 (1.2) | 0 | 16 (9.5) |
| IgM | 1 (1.2) | 0 | 12 (7.1) |
*(n = 38), **(n = 149).
aCL: anticardiolipin antibody, anti-β 2GPI: antibodies against β 2-glycoprotein I, aPS/PT: anti-phosphatidylserine/prothrombin antibodies, and LA: lupus anticoagulant.